SG11202012732UA - Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death - Google Patents
Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte deathInfo
- Publication number
- SG11202012732UA SG11202012732UA SG11202012732UA SG11202012732UA SG11202012732UA SG 11202012732U A SG11202012732U A SG 11202012732UA SG 11202012732U A SG11202012732U A SG 11202012732UA SG 11202012732U A SG11202012732U A SG 11202012732UA SG 11202012732U A SG11202012732U A SG 11202012732UA
- Authority
- SG
- Singapore
- Prior art keywords
- reducing
- protein kinase
- kinase inhibitors
- liver regeneration
- promoting liver
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 210000003494 hepatocyte Anatomy 0.000 title 1
- 210000004185 liver Anatomy 0.000 title 1
- 230000001737 promoting effect Effects 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 230000008929 regeneration Effects 0.000 title 1
- 238000011069 regeneration method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18183712 | 2018-07-16 | ||
| PCT/EP2019/069150 WO2020016243A1 (en) | 2018-07-16 | 2019-07-16 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012732UA true SG11202012732UA (en) | 2021-02-25 |
Family
ID=62975936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012732UA SG11202012732UA (en) | 2018-07-16 | 2019-07-16 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11912701B2 (en) |
| EP (1) | EP3823968A1 (en) |
| JP (1) | JP7365393B2 (en) |
| KR (1) | KR20210035092A (en) |
| CN (1) | CN112424201B (en) |
| AU (1) | AU2019303986B2 (en) |
| BR (1) | BR112020026003A2 (en) |
| CA (1) | CA3104246A1 (en) |
| IL (1) | IL279641B2 (en) |
| MX (1) | MX2020014102A (en) |
| SG (1) | SG11202012732UA (en) |
| WO (1) | WO2020016243A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019149738A1 (en) | 2018-01-31 | 2019-08-08 | Heparegenix Gmbh | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| EP3810139A1 (en) | 2018-06-21 | 2021-04-28 | HepaRegeniX GmbH | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| EP3823968A1 (en) | 2018-07-16 | 2021-05-26 | HepaRegeniX GmbH | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| WO2020239124A1 (en) * | 2019-05-31 | 2020-12-03 | Fochon Pharmaceuticals, Ltd. | SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS |
| JP2023511297A (en) * | 2020-01-15 | 2023-03-17 | ヘパリジェニックス ゲーエムベーハー | Protein kinase inhibitors for promoting liver regeneration or suppressing or preventing hepatocyte death |
| KR20210135092A (en) * | 2020-05-04 | 2021-11-12 | 아주대학교산학협력단 | Toll-like Receptor 7/9 Inhibitory Antagonistic Small Molecule Compounds |
| CN111517977B (en) * | 2020-05-28 | 2023-05-23 | 爱斯特（成都）生物制药股份有限公司 | Method for synthesizing 2, 4-difluoro-3-trimethyl acetamido benzoic acid |
| WO2023194443A1 (en) | 2022-04-06 | 2023-10-12 | Heparegenix Gmbh | Pharmaceutical composition for the treatment of colon and lung cancer |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514981B1 (en) | 1998-04-02 | 2003-02-04 | Sugen, Inc. | Methods of modulating tyrosine protein kinase function with indolinone compounds |
| JP4623962B2 (en) | 2001-10-22 | 2011-02-02 | ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク | Protein kinases and phosphatase inhibitors, methods of designing them, and methods of using them |
| EP1442039A1 (en) | 2001-10-31 | 2004-08-04 | Bayer HealthCare AG | Pyrimido (4,5-b) indole derivatives |
| WO2004058764A1 (en) | 2002-12-27 | 2004-07-15 | Bayer Healthcare Ag | 4-phenyl-pyrimido [4,5-b] indole derivatives |
| SE0401762D0 (en) | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
| FR2876377B1 (en) | 2004-10-11 | 2007-03-16 | Univ Claude Bernard Lyon | NOVEL 9H-PYRIDO [2,3-B] INDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS |
| JP2006282745A (en) | 2005-03-31 | 2006-10-19 | Fuji Photo Film Co Ltd | Cellulose derivative composition, cellulose derivative film, and substituted benzoic acid derivative compound |
| EP1885723A2 (en) | 2005-05-17 | 2008-02-13 | Plexxikon, Inc. | Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors |
| JP5007304B2 (en) | 2005-06-22 | 2012-08-22 | プレキシコン，インコーポレーテッド | Compounds and methods for kinase regulation and indications thereof |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| PE20121126A1 (en) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
| CN104601504B (en) | 2008-07-01 | 2018-12-04 | 爱立信电话股份有限公司 | The method and apparatus of pre-coding matrix is used in MIMO telecommunication system |
| EP2161271A1 (en) | 2008-09-08 | 2010-03-10 | Università Degli Studi Di Milano - Bicocca | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl |
| JP2012520307A (en) | 2009-03-11 | 2012-09-06 | プレキシコン インコーポレーテッド | Pyrrolo [2,3-B] pyridine derivatives for inhibition of RAF kinase |
| WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| CN102574843B (en) | 2009-10-22 | 2015-06-17 | 法博太科制药有限公司 | Fused ring analogues of anti-fibrotic agents |
| BR112012015745A2 (en) | 2009-12-23 | 2016-05-17 | Plexxikon Inc | compounds and methods for kinase modulation, and indications thereof |
| EP2672967B1 (en) | 2011-02-07 | 2018-10-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| WO2012135631A1 (en) | 2011-03-30 | 2012-10-04 | Arrien Pharmaeuticals Llc | Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors |
| EP2508607A1 (en) * | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| CN104053442B (en) | 2011-08-26 | 2017-06-23 | 润新生物公司 | Some chemical entities, composition and method |
| TWI601725B (en) | 2012-08-27 | 2017-10-11 | 加拓科學公司 | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use |
| WO2014047648A1 (en) * | 2012-09-24 | 2014-03-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| SG11201509338QA (en) | 2013-05-30 | 2015-12-30 | Plexxikon Inc | Compounds for kinase modulation, and indications therefor |
| EP2815749A1 (en) * | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| CA2972919A1 (en) | 2015-01-09 | 2016-07-14 | Gilead Apollo, Llc | Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease |
| US9890163B2 (en) | 2015-10-15 | 2018-02-13 | Princeton Drug Discovery Inc | Inhibitors of protein kinases |
| CA3049926A1 (en) * | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN111670183A (en) | 2017-08-07 | 2020-09-15 | Biocad股份公司 | Novel heterocyclic compounds as CDK8/19 inhibitors |
| WO2019149738A1 (en) | 2018-01-31 | 2019-08-08 | Heparegenix Gmbh | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| RU2678455C1 (en) | 2018-06-01 | 2019-01-29 | Сергей Викторович Леонов | N-(3-(5-(4-chlorophenyl)-1n-pyrazolo[3,4-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulphonamide crystalline form, active component, pharmaceutical composition and medicine |
| EP3810139A1 (en) | 2018-06-21 | 2021-04-28 | HepaRegeniX GmbH | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| EP3823968A1 (en) | 2018-07-16 | 2021-05-26 | HepaRegeniX GmbH | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CA3111392A1 (en) | 2018-09-04 | 2020-03-12 | Magenta Therapeutics, Inc. | Aryl hydrocarbon receptor antagonists and methods of use |
| US20220106265A1 (en) | 2018-12-11 | 2022-04-07 | Duke University | Compositions and methods for the treatment of cancer |
| US11370770B2 (en) | 2019-06-24 | 2022-06-28 | Northwestern University | 3-arylindazoles as selective MEK4 inhibitors |
| CA3148780A1 (en) | 2019-07-29 | 2021-02-04 | Bent PFAFFENROT | Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN112778311A (en) | 2019-11-01 | 2021-05-11 | 上海翰森生物医药科技有限公司 | Nitrogen-containing fused ring derivative inhibitor, preparation method and application thereof |
| JP2023511297A (en) | 2020-01-15 | 2023-03-17 | ヘパリジェニックス ゲーエムベーハー | Protein kinase inhibitors for promoting liver regeneration or suppressing or preventing hepatocyte death |
| WO2022150962A1 (en) | 2021-01-12 | 2022-07-21 | Westlake Pharmaceutical (Hangzhou) Co., Ltd. | Protease inhibitors, preparation, and uses thereof |
-
2019
- 2019-07-16 EP EP19742336.1A patent/EP3823968A1/en active Pending
- 2019-07-16 CA CA3104246A patent/CA3104246A1/en active Pending
- 2019-07-16 AU AU2019303986A patent/AU2019303986B2/en active Active
- 2019-07-16 SG SG11202012732UA patent/SG11202012732UA/en unknown
- 2019-07-16 US US17/260,519 patent/US11912701B2/en active Active
- 2019-07-16 JP JP2021501023A patent/JP7365393B2/en active Active
- 2019-07-16 IL IL279641A patent/IL279641B2/en unknown
- 2019-07-16 BR BR112020026003-7A patent/BR112020026003A2/en unknown
- 2019-07-16 CN CN201980047654.0A patent/CN112424201B/en active Active
- 2019-07-16 WO PCT/EP2019/069150 patent/WO2020016243A1/en active Application Filing
- 2019-07-16 KR KR1020207036713A patent/KR20210035092A/en unknown
- 2019-07-16 MX MX2020014102A patent/MX2020014102A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11912701B2 (en) | 2024-02-27 |
| BR112020026003A2 (en) | 2021-03-23 |
| AU2019303986A1 (en) | 2021-01-14 |
| JP7365393B2 (en) | 2023-10-19 |
| US20220281864A1 (en) | 2022-09-08 |
| WO2020016243A1 (en) | 2020-01-23 |
| EP3823968A1 (en) | 2021-05-26 |
| JP2021529815A (en) | 2021-11-04 |
| IL279641B1 (en) | 2023-12-01 |
| MX2020014102A (en) | 2021-05-27 |
| KR20210035092A (en) | 2021-03-31 |
| CN112424201A (en) | 2021-02-26 |
| IL279641B2 (en) | 2024-04-01 |
| CN112424201B (en) | 2024-04-02 |
| CA3104246A1 (en) | 2020-01-23 |
| AU2019303986B2 (en) | 2024-02-22 |
| IL279641A (en) | 2021-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276353A (en) | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
| IL279641A (en) | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
| ZA201905078B (en) | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
| IL278116A (en) | Pyridazinones as parp7 inhibitors | |
| IL291017A (en) | Benzolactam compounds as protein kinase inhibitors | |
| IL290190A (en) | Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
| IL276509A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| IL281108A (en) | Compositions and methods for enhancing donor oligonucleotide-based gene editing | |
| ZA202000107B (en) | Aminothiazole compounds as protein kinase inhibitors | |
| ZA201808014B (en) | Adenine derivatives as protein kinase inhibitors | |
| EP3288931A4 (en) | Certain protein kinase inhibitor | |
| IL264593A (en) | Pharmaceutical compositions comprising akt protein kinase inhibitors | |
| ZA201808238B (en) | Certain protein kinase inhibitors | |
| ZA201904558B (en) | Methods and compositions for preventing or minimizing epithelial-mesenchymal transition | |
| EP3555092A4 (en) | Protein kinase inhibitors | |
| PL3632912T3 (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| GB201914388D0 (en) | Kinase inhibitors | |
| GB202111043D0 (en) | Protein interaction inhibitors | |
| GB202110970D0 (en) | Protein interaction inhibitors |